Lipitor as a Treatment for Alzheimer's Disease
The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Primary Purpose: Treatment
|Official Title:||Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease|
|Study Start Date:||October 2000|
|Estimated Study Completion Date:||August 2004|
This study is a phase II, placebo controlled, double-blind, one year trial investigating the effect of HmG-CoA reductase inhibitor atorvastatin calcium in the treatment of persons with possible or probable Alzheimer's disease. Subjects may continue to take stable doses of Aricept and Exelon. Following enrollment, participants will make visits to the study center every three months for blood tests and neuropsychological testing.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00024531
|United States, Arizona|
|Sun Health Research Institute|
|Sun City, Arizona, United States, 85351|
|Principal Investigator:||David L Sparks, PhD||Sun Health Research Institute|